Welcome to Issue 3 of Everyday Urology - Oncology Insights which focuses on the exceptionally rapid and groundbreaking advances in both advanced prostate and bladder cancer evaluation and management. 

Petros Grivas’ cover article, Updates on Immunotherapy for Urothelial Cancer, not only succinctly reviews the five new approved immuno-oncology therapies (IO), aka checkpoint (PD pathway) inhibitors and their milestone clinical trials, but also offers guidance regarding treatment selection strategy as well as IO selection within the context of chemotherapeutic options.  Additionally, he discusses a basis for monitoring efficacy of response, potential biomarkers and genomic markers predictive of patient benefit and also reviews the ongoing possibilities for combination strategies. Clearly, both advanced bladder and kidney cancer care information and subsequent
Optimizing the patient clinical outcome (prolonging survival, preserving quality of life, and preventing complications) while avoiding excessive healthcare economic burden is tantamount to the overall improvement of the healthcare system.  Certainly, combining an integrative, multidisciplinary approach, which can attain these aforementioned goals will align with the “Triple Aim”, which proposes that improving the U.S. health care system requires simultaneous pursuit of three aims: improving the experience of care, improving the health of populations, and reducing per capita costs of health care.  

Our first issue of 2017 emphasizes a well-known, yet an evolving and important, theme: optimizing the successful multidisciplinary collaboration amongst oncologic physicians; and furthermore, the importance of patient involvement, also known as, patient-physician shared decision making (and assuredly, successful integrated care).  This multidimensional approach to decision making and treatment has numerous advantages in all phases of the patient care experience, the physician expectation of successful genitourinary oncology outcomes, and efficiency for the healthcare ecosystem.  The authors of our three featured articles in this issue include the specialties of: urology, cardiology and nuclear medicine.

Over the past year, we’ve been honored to provide you with the inaugural issues of Everyday Urology-Oncology Insights. This fourth issue completes our publications for 2016—a year highlighted by important developments in the optimal management and treatment of patients with genitourinary cancers. Everyday Urology-Oncology Insights has strived in our inaugural year of publication to provide our readership with timely articles, written by internationally renowned GU oncology experts. I’d like to thank our editorial team and our advisory board for their dedication to selecting and reviewing the relevant content of interest for urologists, medical oncologists, radiation oncologists, and radiologists.
In this issue of Everyday Urology-Oncology Insights, we will share with you several articles which are based upon recent presentations from the CME course at the annual Large Urology Group Practice Association (LUGPA) meeting held this past November in Chicago, Illinois. I was honored to be the co-chairman along with my colleague, Dr. David Chaikin. This year’s LUGPA CME program was entitled: “Optimizing Bladder Disease Management”.
Since the inaugural publication of Everyday Urology-Oncology Insights, we have received wonderful feedback and insights from our readers and colleagues, and I am extremely appreciative for all of the suggestions. We will strive to present ongoing educational content which should enhance your specific practice model, and we will always look forward to receiving your feedback for this in order to ensure that this quarterly publication provides you with actionable and useful information.
Welcome to the inaugural issue of Everyday UrologyOncology Insights, brought to you by Digital Science Press, Inc, publishers of UroToday.com. For the past 13 years, UroToday has demonstrated its commitment to providing accurate, timely, evidence-based urology and oncology information to the global community of healthcare providers. With its inception in 2003, there was a recognition that there are a multitude of ongoing scientific publications and medical conferences; nevertheless, an easy to access daily platform to acknowledge, report and accommodates this content did not exist. UroToday.com initiated its web based platform to succinctly aggregate the contemporaneous and most relevant urology content on a real time, daily basis in order to allow busy clinicians to remain up to date with the newest research, approvals, and meeting information.